# Simon Faissner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4029765/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 45<br>papers | 1,155<br>citations | 393982<br>19<br>h-index | 395343<br>33<br>g-index |
| 52<br>all docs | 52<br>docs citations | 52<br>times ranked | 2020<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nature Reviews Drug Discovery, 2019, 18, 905-922. | 21.5 | 265 |
| 2 | Multi-target-directed phenolâ€“triazole ligands as therapeutic agents for Alzheimer's disease. Chemical Science, 2017, 8, 5636-5643. | 3.7 | 79 |
| 3 | Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010. CNS Drugs, 2018, 32, 269-287. | 2.7 | 65 |
| 4 | Statin pretreatment is associated with better outcomes in large artery atherosclerotic stroke. Neurology, 2016, 86, 1103-1111. | 1.5 | 59 |
| 5 | Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Therapeutic Advances in Neurological Disorders, 2015, 8, 233-238. | 1.5 | 55 |
| 6 | Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis. Journal of Central Nervous System Disease, 2014, 6, JCNSD.S14049. | 0.7 | 50 |
| 7 | Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic. Nature Communications, 2017, 8, 1990. | 5.8 | 50 |
| 8 | Progressive multiple sclerosis: latest therapeutic developments and future directions. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641987832. | 1.5 | 45 |
| 9 | Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model. Journal of Neuroinflammation, 2018, 15, 183. | 3.1 | 39 |
| 10 | Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?. Multiple Sclerosis Journal, 2018, 24, 1543-1556. | 1.4 | 33 |
| 11 | Teriflunomide and monomethylfumarate target HIV-induced neuroinflammation and neurotoxicity. Journal of Neuroinflammation, 2017, 14, 51. | 3.1 | 31 |
| 12 | Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses. Journal of Neurology, 2016, 263, 1092-1098. | 1.8 | 29 |
| 13 | Immunoadsorption in patients with neuromyelitis optica spectrum disorder. Therapeutic Advances in Neurological Disorders, 2016, 9, 281-286. | 1.5 | 29 |
| 14 | Oral Therapies for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a032011. | 2.9 | 29 |
| 15 | Statin Pretreatment and Microembolic Signals in Large Artery Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1415-1422. | 1.1 | 27 |
| 16 | Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e85. | 3.1 | 25 |
| 17 | COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis. Journal of Neurology, 2022, 269, 1774-1775. | 1.8 | 25 |
| 18 | Smad7 in intestinal CD4<sup>+</sup>T cells determines autoimmunity in a spontaneous model of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25860-25869. | 3.3 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e551. | 3.1 | 20 |
| 20 | â€œLiberation treatmentâ€•for chronic cerebrospinal venous insufficiency in multiple sclerosis: the truth will set you free. Brain and Behavior, 2015, 5, 3-12. | 1.0 | 19 |
| 21 | Amphiphysin-positive paraneoplastic myelitis and stiff-person syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e285. | 3.1 | 19 |
| 22 | Cytoplasmic HIV-RNA in monocytes determines microglial activation and neuronal cell death in HIV-associated neurodegeneration. Experimental Neurology, 2014, 261, 685-697. | 2.0 | 17 |
| 23 | Clozapine Regulates Microglia and Is Effective in Chronic Experimental Autoimmune Encephalomyelitis. Frontiers in Immunology, 2021, 12, 656941. | 2.2 | 15 |
| 24 | Interferon-beta affects mitochondrial activity in CD4<sup>+</sup> lymphocytes: Implications for mechanism of action in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1262-1270. | 1.4 | 10 |
| 25 | Longitudinal Evaluation of the Effect of Tricyclic Antidepressants and Neuroleptics on the Course of Huntingtonâ€™s Diseaseâ€”Data from a Real World Cohort. Brain Sciences, 2021, 11, 413. | 1.1 | 10 |
| 26 | Multiple sclerosis is not associated with an increased risk for severe COVID-19: a nationwide retrospective cross-sectional study from Germany. Neurological Research and Practice, 2021, 3, 42. | 1.0 | 10 |
| 27 | Monitoring Peripheral Blood CD4+ Intracellular Adenosine Triphosphate Concentration in Patients with Psoriasis Treated with Fumaric Acid Esters. Acta Dermato-Venereologica, 2012, 92, 364-366. | 0.6 | 8 |
| 28 | The impact of the COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110306. | 1.5 | 8 |
| 29 | Risk of perioperative neck hematoma in TIA and non-disabling stroke patients with symptomatic carotid artery stenosis undergoing endarterectomy within 14Âdays from cerebrovascular event.. Journal of the Neurological Sciences, 2020, 409, 116590. | 0.3 | 7 |
| 30 | Rituximab postprogressive multifocal leukoencephalopathy: a Feasible therapeutic option in selected cases. Therapeutic Advances in Neurological Disorders, 2014, 7, 289-291. | 1.5 | 6 |
| 31 | Endocarditis following ocrelizumab in relapsing-remitting MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, . | 3.1 | 6 |
| 32 | Progressive Retinal and Optic Nerve Damage in a Mouse Model of Spontaneous Opticospinal Encephalomyelitis. Frontiers in Immunology, 2021, 12, 759389. | 2.2 | 6 |
| 33 | â€œPunched nerve syndromeâ€•as contributing factor for â€œSaturday night palsyâ€• Journal of the Neurological Sciences, 2016, 368, 173-174. | 0.3 | 5 |
| 34 | General principles and escalation options of immunotherapy in autoantibody-associated disorders of the CNS. Neurological Research and Practice, 2019, 1, 32. | 1.0 | 5 |
| 35 | Immunotherapy Improves Cognitive Function in Secondary Progressive Multiple Sclerosis. CNS Neuroscience and Therapeutics, 2016, 22, 1019-1022. | 1.9 | 4 |
| 36 | Differential Diagnosis of Choreaâ€”HIV Infection Delays Diagnosis of Huntingtonâ€™s Disease by Years. Brain Sciences, 2021, 11, 710. | 1.1 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Hypoechogenicity of brainstem raphe in long-COVID syndromeâ€“less common but independently associated with depressive symptoms: a cross-sectional study. Journal of Neurology, 2022, 269, 4604-4610. | 1.8 | 4 |
| 38 | 1,25-OH 2 vitamin D 3 and AKT-inhibition increase glucocorticoid induced apoptosis in a model of T-cell acute lymphoblastic leukemia (ALL). Leukemia Research Reports, 2018, 9, 38-41. | 0.2 | 3 |
| 39 | Teaching Neuro Images : Sonographic â€œretrobulbar spot signâ€•in differentiating etiologies of sudden visual loss. Neurology, 2014, 82, e153-4. | 1.5 | 2 |
| 40 | Binding patterns and functional properties of human antibodies to AQP4 and MOG on murine optic nerve and retina. Journal of Neuroimmunology, 2020, 342, 577194. | 1.1 | 2 |
| 41 | Atypical Occipital Calcinosis in a Caucasian Individual with Probable Diffuse Neurofibrillary Tangles with Calcification. Journal of the American Geriatrics Society, 2014, 62, 2022-2024. | 1.3 | 1 |
| 42 | Letter to the editor regarding Gholamzad et al., â€œA comprehensive review on the treatment approaches of multiple sclerosis: currently and in the futureâ€• Inflammation Research, 2020, 69, 153-153. | 1.6 | 1 |
| 43 | Resurrection of sildenafil: potential for Huntingtonâ€™s Disease, too?. Journal of Neurology, 2022, 269, 5144-5150. | 1.8 | 1 |
| 44 | Clinical commentary on â€˜Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosisâ€™. Multiple Sclerosis Journal, 2018, 24, 1385-1386. | 1.4 | 0 |
| 45 | Delayed Diagnosis of Anti-Hu Antibodies in a Young Patient With Cerebellar Atrophy. Pediatric Neurology, 2020, 111, 27-29. | 1.0 | 0 |